A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Phase I Clinical Study in Healthy Chinese Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of HBM9378 (SKB378) After Subcutaneous Administration
Latest Information Update: 16 Jan 2025
At a glance
- Drugs HBM-9378 (Primary)
- Indications Asthma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Harbour BioMed
Most Recent Events
- 11 Jan 2025 According to a Sichuan Kelun-Biotech Biopharmaceutical media release, company completed phase 1 trial in China under IND approval from the NMPA for the treatment of moderate-to-severe asthma.
- 29 Aug 2024 Status changed to completed.
- 28 Sep 2022 New trial record